MedWatch reports: Another record year

19 April 2023

Alphalyse is growing on all parameters

Alphalyse is having yet another record year, according to MedWatch, a business media covering the pharmaceutical and medtech industries:

Gross profit is increasing, profits are rising, and the number of employees is growing. But that's standard practice for Alphalyse.

The contract research organization, which offers protein analysis and identification of impurities in biological drugs, ended 2022 with a solid 27.4 percent gross profit increase compared to the previous year. This parameter sets a new record for Alphalyse once again.

In 2022, Alphalyse strengthened the company's focus on servicing key customers who develop and market new biological drugs.

At the same time, in 2022, Alphalyse received a GMP accreditation from the Danish Medicines Agency.

"This is of crucial importance in relation to our strategy to support our customers with HCP analysis throughout the development phase, and also for release testing when the drug is on the market," wrote management in the financial report.

A screenshot of an article headline from the business media MedWatch. The headline states: "Another record year for Alphalyse." The accompanying photo shows two smiling Alphalyse employees working in the laboratory.

Talk to us

Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.

I would like an
This field is for validation purposes and should be left unchanged.